XERS Stock Analysis: Buy, Sell, or Hold?
XERS - Xeris Biopharma Holdings, Inc. Common Stock
$5.60
0.20 (3.70%)
▲
5d:
-0.18%
30d:
-8.5%
90d:
-24.02%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
XERS is down 5.7% this week, but smart money is accumulating calls. Top strike: $7.5 2026-05-15 with 23 OI. Call ratio: 100% View Scanner →
Strength: 7.9/10
Get Alerted When XERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: XERS trading at deep discount. Market pricing in -9.5% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: XERS trading at deep discount. Market pricing in -9.5% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.72
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$9.14
38.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XERS is currently trading at $5.60, which is considered slightly low relative to its 30-day fair value range of $5.40 to $6.34. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.1) compared to its historical average (20.4). Remarkably, the market is currently pricing in an annual earnings decline of 9.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, XERS is in a downtrend. The price is approaching resistance at $5.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.14 (+99.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XERS is in a downtrend. The price is approaching resistance at $5.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.14 (+99.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$5.40 -
$6.34
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 99.0% below Wall St target ($11.14)
Fair Price Analysis
30-Day Fair Range
$5.40 -
$6.34
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.25
Resistance Level
$5.69
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.11
Wall Street Target
$11.14
(+99.0%)
Revenue Growth (YoY)
42.8%
Profit Margin
0.2%
Valuation Discount vs History
-9.5% cheaper
PE vs Historical
15.1 vs 20.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-9.5%
(market-implied from PE analysis)
1-Year Target
$5.07
(-10%)
2-Year Target
$4.59
(-18%)
3-Year Target
$4.15
(-26%)
3-Yr Target (if PE normalizes)
(PE: 15→20)
$5.60
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 160.4%)
$27.95
(+399%)
Base:
(SPY PE: 15.1, Growth: 160.4%)
$18.90
(+238%)
Bear:
(PE: 12.8, Growth: 160.4%)
$16.07
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.1 to 20.4
Stabilization Target:
$7.56
(+35.0%)
PE Expansion Potential:
+35.0%
Share & Embed Analysis
Last updated: March 30, 2026 6:42 PM ET
Data refreshes hourly during market hours. Next update: 7:42 PM
Data refreshes hourly during market hours. Next update: 7:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Beth Hecht
SELL
16667 shares
2026-03-02
Beth Hecht
SELL
16667 shares
2026-02-02
Kevin Mcculloch
SELL
15000 shares
2026-01-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |